Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00479622 · ClinicalTrials.gov registry record · Phase 1
Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00479622 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT00479622, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.
Interventions
- DRUG TRU-015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00479622
The ClinicalTrials.gov registry entry for NCT00479622 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRU-015 is the first listed.
NCT00479622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00479622 about?
NCT00479622 is a clinical study titled "Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus". The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.
What is the current status of trial NCT00479622?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-08. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00479622?
The interventions under investigation include: TRU-015 (DRUG).
Who is sponsoring clinical trial NCT00479622?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.